Vital Transformation
@vitaltransform.bsky.social
Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organization to help you find answers to hard-to-solve problems.
Small‑molecule drugs face Medicare negotiations four years earlier than biologics, slashing early‑stage funding by nearly 70%. Affordable pills are disappearing, and vital therapies are at risk.
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
May 5, 2025 at 2:02 PM
Small‑molecule drugs face Medicare negotiations four years earlier than biologics, slashing early‑stage funding by nearly 70%. Affordable pills are disappearing, and vital therapies are at risk.
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
Read the PhRMA article: buff.ly/1mGUHHS
@weworkforhealth
Medicare’s nine-year price cap erodes ~40% of a small-molecule project’s value before trials, sidelining therapies for aging - extending it to 13 years would restore innovators’ financial runway.
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
May 1, 2025 at 1:03 PM
Medicare’s nine-year price cap erodes ~40% of a small-molecule project’s value before trials, sidelining therapies for aging - extending it to 13 years would restore innovators’ financial runway.
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
Read more: buff.ly/4w5EV5P
#IRA #DrugPricing #Pharma #Health #Technology #Research #Economics
President Trump’s new order moves to end the IRA’s “pill penalty.” Our research shows median investment in key small-molecule therapies fell from $175M to $45M. The policy aims to bring that investment back: buff.ly/5oFWhrA
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
April 30, 2025 at 1:04 PM
President Trump’s new order moves to end the IRA’s “pill penalty.” Our research shows median investment in key small-molecule therapies fell from $175M to $45M. The policy aims to bring that investment back: buff.ly/5oFWhrA
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
#IRA #DrugPricing #Pharma#Healthcare #Health #Research #Economics
Reuters reports the Trump administration aims to revise Medicare’s drug pricing timeline. Our research shows a 74% drop in NME investment post-IRA. Shorter pricing windows shift capital.
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
April 28, 2025 at 1:03 PM
Reuters reports the Trump administration aims to revise Medicare’s drug pricing timeline. Our research shows a 74% drop in NME investment post-IRA. Shorter pricing windows shift capital.
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
Reusters Report: buff.ly/gcqHOI5
VT Research: buff.ly/CrTmhOr
#IRA #DrugPricing #Pharma #Biopharma #Healthcare
The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with Steve Usdin to unpack how this shift skews R&D incentives and future therapies.
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
April 27, 2025 at 1:01 PM
The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with Steve Usdin to unpack how this shift skews R&D incentives and future therapies.
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
Listen here: buff.ly/9ZuZR3K
#IRA #DrugPricing #Pharma #PillPenalty
We spoke with @steveusdin1 about the effects of IRA’s 9-year vs 13-year protection. Our research shows it channels early-stage funding to biologics over pills. Lower costs undermine future development
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
April 26, 2025 at 1:01 PM
We spoke with @steveusdin1 about the effects of IRA’s 9-year vs 13-year protection. Our research shows it channels early-stage funding to biologics over pills. Lower costs undermine future development
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
Listen to the full conversation: buff.ly/9ZuZR3K
@weworkforhealth #IRA #DrugPricing #PillPenalty
Early-stage trial launches dropped 35% after the IRA. The orange line shows the decline in activity, diverging from the pre-IRA trend. Our study connects this shift to reduced investment in small molecule innovation: buff.ly/lkhuOjP
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
April 25, 2025 at 1:05 PM
Early-stage trial launches dropped 35% after the IRA. The orange line shows the decline in activity, diverging from the pre-IRA trend. Our study connects this shift to reduced investment in small molecule innovation: buff.ly/lkhuOjP
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
#IRA #DrugPricing #Pharma #Biopharma #Health #PillPenalty
The IRA was meant to help seniors, but it’s decreasing early investment in treatments for age-related diseases. Small molecule therapies for conditions affecting largely Medicare patients saw a 74% drop in median investment.
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
April 23, 2025 at 5:03 PM
The IRA was meant to help seniors, but it’s decreasing early investment in treatments for age-related diseases. Small molecule therapies for conditions affecting largely Medicare patients saw a 74% drop in median investment.
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
More from We Work for Health: buff.ly/INAKWj9
#IRA #PillPenalty
Suneet Varma of Pfizer Oncology says IRA-related factors make biologics a more stable investment. Our research shows small molecule funding has dropped 68% since the law passed.
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
April 21, 2025 at 1:03 PM
Suneet Varma of Pfizer Oncology says IRA-related factors make biologics a more stable investment. Our research shows small molecule funding has dropped 68% since the law passed.
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
Read more: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #PillPenalty
The IRA triggered a 74% drop in investment for pills treating Medicare patients. Alzheimer's, cancer, and other therapies are now at risk. Equal timelines could help restore progress.
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
April 18, 2025 at 6:02 PM
The IRA triggered a 74% drop in investment for pills treating Medicare patients. Alzheimer's, cancer, and other therapies are now at risk. Equal timelines could help restore progress.
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
📄https://buff.ly/Agz6GuJ
#IRA #DrugPricing #Pharma #PIllPenalty #Research
The IRA sets Medicare’s maximum fair price at year 9 for small molecule drugs, 4 years sooner than for biologics.
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
April 17, 2025 at 6:02 PM
The IRA sets Medicare’s maximum fair price at year 9 for small molecule drugs, 4 years sooner than for biologics.
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
Since then, early-stage small molecule funding has dropped from $2B to $640M. Expect fewer new treatments for seniors by 2030. Read more: buff.ly/mDCX8Ws
Pills and tablets save lives.
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
April 16, 2025 at 7:03 PM
Pills and tablets save lives.
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
The IRA changed how drugs are priced.
Investors had less time to profit, so they pulled back fast.
Drug development slowed across the industry.
Fewer new medicines are being made.
Patients — especially seniors — are losing out.
📄 Press release: buff.ly/zDkO8zv
Why has early-stage funding for small molecule drugs dropped 68%, from $2B to $640M?
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
April 15, 2025 at 7:01 PM
Why has early-stage funding for small molecule drugs dropped 68%, from $2B to $640M?
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
The IRA’s 9-year price-setting window shortens their return period, increasing risk and driving early-stage capital elsewhere.
Read our latest findings: buff.ly/mDCX8Ws
#IRA #DrugPricing #Pharma #Health
Our new data shows small molecule investment has dropped 68%, 74% for Medicare-focused treatments, since the IRA was introduced.
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
April 15, 2025 at 1:02 PM
Our new data shows small molecule investment has dropped 68%, 74% for Medicare-focused treatments, since the IRA was introduced.
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
Removing the pill penalty could boost FDA approvals by 21%.
Read more from We Work for Health: buff.ly/Didvv88
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Health
📢 New VT Research!
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
April 14, 2025 at 3:02 PM
📢 New VT Research!
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
The IRA is driving a 68% aggregate drop in early-stage funding for small molecule drugs, with early-stage clinical trials also in decline. Our latest report shows how this puts future treatments for seniors at risk.
Read more: buff.ly/pkV8vHB
#IRA #DrugPricing #Pharma #Health
The IRA is creating consequences for patients and innovation. By imposing earlier price controls on certain medicines, it discourages investment in small molecules, leading to fewer options and higher costs for patients.
Read more from the CAHC: buff.ly/xCnZcWX
Read more from the CAHC: buff.ly/xCnZcWX
April 13, 2025 at 2:03 PM
The IRA is creating consequences for patients and innovation. By imposing earlier price controls on certain medicines, it discourages investment in small molecules, leading to fewer options and higher costs for patients.
Read more from the CAHC: buff.ly/xCnZcWX
Read more from the CAHC: buff.ly/xCnZcWX
Duane Schulthess joined a Capitol Hill panel on the EPIC Act, sharing VT data showing a 70% drop in small molecule investment since the IRA. The EPIC Act aims to protect access and restore innovation.
Read more: buff.ly/MBxjCMB
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Healthcare #Health
Read more: buff.ly/MBxjCMB
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Healthcare #Health
April 11, 2025 at 7:14 PM
Duane Schulthess joined a Capitol Hill panel on the EPIC Act, sharing VT data showing a 70% drop in small molecule investment since the IRA. The EPIC Act aims to protect access and restore innovation.
Read more: buff.ly/MBxjCMB
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Healthcare #Health
Read more: buff.ly/MBxjCMB
#IRA #DrugPricing #Pharma #Biopharma #HealthTech #Healthcare #Health
🔥 Happening tomorrow in Washington, D.C.! Don’t miss this crucial conversation on the EPIC Act and the IRA’s pill penalty—featuring Duane Schulthess on the panel. Early-stage investment in small-molecule drugs is falling, and access to future therapies is on the line.
✅ Sign up now: buff.ly/0ubX7rS
✅ Sign up now: buff.ly/0ubX7rS
April 8, 2025 at 5:02 PM
🔥 Happening tomorrow in Washington, D.C.! Don’t miss this crucial conversation on the EPIC Act and the IRA’s pill penalty—featuring Duane Schulthess on the panel. Early-stage investment in small-molecule drugs is falling, and access to future therapies is on the line.
✅ Sign up now: buff.ly/0ubX7rS
✅ Sign up now: buff.ly/0ubX7rS
📉 Catch Duane Schulthess at a panel on the EPIC Act and the IRA’s impact. VT’s research shows shrinking funding for small-molecule innovation. Join We Work for Health for this important discussion.
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
April 7, 2025 at 3:01 PM
📉 Catch Duane Schulthess at a panel on the EPIC Act and the IRA’s impact. VT’s research shows shrinking funding for small-molecule innovation. Join We Work for Health for this important discussion.
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
🚨 Duane Schulthess joins a D.C. panel on the EPIC Act and IRA’s “pill penalty.” New VT research shows declining investment in small-molecule drugs for seniors. Join this We Work for Health–hosted event to explore solutions.
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
April 3, 2025 at 1:03 PM
🚨 Duane Schulthess joins a D.C. panel on the EPIC Act and IRA’s “pill penalty.” New VT research shows declining investment in small-molecule drugs for seniors. Join this We Work for Health–hosted event to explore solutions.
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
📋 RSVP for 4/10/25: buff.ly/0ubX7rS
📉 The IRA’s pill penalty could raise Medicare patients’ drug costs by up to 76%, according to a new report from the Council for Affordable Health Coverage. This backs up what we’ve found: the IRA is harming small molecule innovation and patient access.
Read the full report: buff.ly/HqPbzty
#Pharma
Read the full report: buff.ly/HqPbzty
#Pharma
April 2, 2025 at 8:00 PM
📉 The IRA’s pill penalty could raise Medicare patients’ drug costs by up to 76%, according to a new report from the Council for Affordable Health Coverage. This backs up what we’ve found: the IRA is harming small molecule innovation and patient access.
Read the full report: buff.ly/HqPbzty
#Pharma
Read the full report: buff.ly/HqPbzty
#Pharma
Dan Leonard said it best during the recent IQVIA webinar—and our research supports it.
📺 Webinar: buff.ly/9uBaSRe
📄 Full analysis: buff.ly/VJ4ovQg
📺 Webinar: buff.ly/9uBaSRe
📄 Full analysis: buff.ly/VJ4ovQg
March 29, 2025 at 2:01 PM
Dan Leonard said it best during the recent IQVIA webinar—and our research supports it.
📺 Webinar: buff.ly/9uBaSRe
📄 Full analysis: buff.ly/VJ4ovQg
📺 Webinar: buff.ly/9uBaSRe
📄 Full analysis: buff.ly/VJ4ovQg
Patients were promised savings—but those dollars aren’t going back into healthcare. 💊
IRA-generated funds are often diverted to state budgets, not used to lower medicine costs.
🔗 Read the We Work For Health recap: buff.ly/60sOy1R
#IRA #DrugPricing #Pharma #Biopharma #PillPenalty #Healthcare
IRA-generated funds are often diverted to state budgets, not used to lower medicine costs.
🔗 Read the We Work For Health recap: buff.ly/60sOy1R
#IRA #DrugPricing #Pharma #Biopharma #PillPenalty #Healthcare
March 26, 2025 at 5:04 PM
Patients were promised savings—but those dollars aren’t going back into healthcare. 💊
IRA-generated funds are often diverted to state budgets, not used to lower medicine costs.
🔗 Read the We Work For Health recap: buff.ly/60sOy1R
#IRA #DrugPricing #Pharma #Biopharma #PillPenalty #Healthcare
IRA-generated funds are often diverted to state budgets, not used to lower medicine costs.
🔗 Read the We Work For Health recap: buff.ly/60sOy1R
#IRA #DrugPricing #Pharma #Biopharma #PillPenalty #Healthcare
When innovation stalls, new treatments vanish. In 2022, PhRMA warned the Inflation Reduction Act would harm R&D. Our research shows funding has plummeted and trials are disappearing.
🔗 Our research: buff.ly/LjF33Go
(Image from PhRMA)
#Pharma
🔗 Our research: buff.ly/LjF33Go
(Image from PhRMA)
#Pharma
March 24, 2025 at 2:00 PM
When innovation stalls, new treatments vanish. In 2022, PhRMA warned the Inflation Reduction Act would harm R&D. Our research shows funding has plummeted and trials are disappearing.
🔗 Our research: buff.ly/LjF33Go
(Image from PhRMA)
#Pharma
🔗 Our research: buff.ly/LjF33Go
(Image from PhRMA)
#Pharma
Testing new treatments for rare conditions is difficult with so few patients. PRIME-ROSE merges data across hospitals to create larger, more effective trials. This speeds up research and expands access to life-saving cancer treatments.
🎥 Listen here: buff.ly/ZPWChNR
🎥 Listen here: buff.ly/ZPWChNR
March 24, 2025 at 8:01 AM
Testing new treatments for rare conditions is difficult with so few patients. PRIME-ROSE merges data across hospitals to create larger, more effective trials. This speeds up research and expands access to life-saving cancer treatments.
🎥 Listen here: buff.ly/ZPWChNR
🎥 Listen here: buff.ly/ZPWChNR